Jefferies lowered the firm's price target on RxSight to $6.50 from $7.50 and keeps a Hold rating on the shares. Q2 preliminary results missed due to competitive trialing and macro pressures, as the company expects the trailing pressures to continue and lowered guidance by about 10% for the year, or an implied roughly 18% for H2, the analyst tells investors in a research note. The firm added that monthly utilization was the lowest it's been in four years, with implied H2 utilization down roughly 10% year-over-year.
